Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.42 |
| ▸ | KDR | P35968 | 10/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31690571 | 1.00 | AAK1 (0.42) | AAK1KDRMAPK14BRAFTNNI3K | |
| SCHEMBL21610156 | 0.86 | KDR (0.42) | AAK1KDRMAPK14BRAFTNNI3K | |
| SCHEMBL21611232 | 0.86 | SUV39H2 (0.40) | AAK1KDRMAPK14BRAFTNNI3K | |
| SCHEMBL21611230 | 0.83 | AAK1 (0.39) | AAK1KDRMAPK14 | |
| SCHEMBL21611233 | 0.79 | KDR (0.42) | KDRMAPK14BRAFTNNI3KMET | |
| SCHEMBL21610196 | 0.78 | AAK1 (0.45) | AAK1KDRMAPK14BRAFTNNI3K | |
| SCHEMBL21610150 | 0.76 | KDR (0.41) | AAK1KDRMETKMOGRM4 | |
| SCHEMBL21610148 | 0.76 | KDR (0.41) | AAK1KDRMETKMOGRM4 | |
| SCHEMBL21610191 | 0.74 | ATR (0.44) | AAK1 | |
| SCHEMBL23927067 | 0.74 | MAPT (0.44) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| EP-3947365-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | Bionomics Limited (AU) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | GABRE, GRIN2C, GRIN2A | AAK1 2592/4885KDR 4670/4885MAPK14 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.